Compugen Q2 net loss widens to $3.9 million | GenomeWeb

NEW YORK, Sept. 5 — Israeli bioinformatics company Compugen (Nasdaq: CGEN) said on Tuesday its second quarter net loss widened to $3.9 million, or 61 cents per basic and diluted share, from $2.0 million, or 34 cents per basic and diluted share, in the year ago period.

The company said its second quarter revenues more than doubled to $1.4 million from $655,000 in second-quarter 1999.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.